Waiting room video cuts antibiotic expectations but not prescriptions
Watching a brief video about antibiotic treatment prior to a family practitioner visit reduced patients' expectations about receiving antibiotics for upper respiratory tract infections (URTIs) but had no influence on physician prescribing, according to a randomized controlled trial published this week in the Annals of Family Medicine.
In the three-armed trial, conducted by researchers at the University of Auckland in New Zealand, patients at two family practices in Auckland were randomly allocated to watch one of three video presentations on a tablet device immediately before their consultation. One video was on the futility of antibiotic treatment for URTIs, the other described the adverse effects associated with antibiotics, and the third was on the benefits of healthy diet and exercise. Before and after viewing the videos, patients filled out a questionnaire and were asked to rate, using a Likert scale, the strength of their belief that antibiotics are effective for treating URTIs and their desire to receive an antibiotic.
A total of 325 patients participated in the trial. Likert scores for patients' agreement with the statement "I wish to receive antibiotics for my/my child's cold/flu" before viewing the presentations was similar across all three groups, with a mean score of 3. After viewing the presentations, the mean reduction in Likert score for those who viewed the futility video (1.1; 95% confidence interval [CI], 0.8 to 1.3) or the adverse-effects video (0.7; 95% CI, 0.4 to 0.9) was significantly greater than that for those who viewed the control video (0.1; 95% 0.0 to 0.3). The effect was also observed when the analysis was restricted to the parents of 91 child participants.
Among the 306 patients who completed the post-presentation questionnaire, 30% received an antibiotic prescription. There was no significant difference in the proportion between the futility group (31%), adverse-effects group (28%), and control group (32%).
"Although we reduced patients' expectations for an antibiotic prescription, doing so did not reduce antibiotic prescribing by family practitioners," the study authors wrote, while noting that the study was not primarily designed to examine prescribing. "This finding is surprising given that patients' expectations to receive antibiotics are stated to be the main driver of antibiotic prescribing for URTIs."
The authors suggest it's possible that participants provided socially desirable responses on the questionnaires but made their real expectations clear in the consultation with family practitioners.
May 10 Ann Fam Med study
Spanish study finds high rate of inappropriate antibiotics in COVID patients
A study of COVID-19 patients in Spain during the early months of the pandemic found frequent inappropriate antibiotic use, Spanish researchers reported yesterday in PLOS One.
Of the 13,932 COVID-19 patients treated at Spanish hospitals from Mar 1 through Jun 23, 2020, 10,885 (78.1%) received systemic antibiotics other than macrolides, with 6,116 (43.9%) appropriately prescribed antibiotics and 4,769 (34.2%) inappropriately prescribed antibiotics.
Analysis of independent risk factors for inappropriate antibiotic prescribing identified admission from February through March (odds ratio [OR], 1.54; 95% CI, 1.18 to 2.00), younger age (OR, 0.98; 95% CI, 0.97 to 0.99), absence of comorbidity (OR, 1.43; 95% CI, 1.05 to 1.94), dry cough (OR, 2.51; 95% CI, 1.94 to 3.26), fever (OR, 1.33; 95% CI, 1.13 to 1.56), dyspnea (OR, 1.31; 95% CI, 1.04 to 1.69), flu-like symptoms (OR, 2.70; 95% CI, 1.75 to 4.17), and elevated C-reactive protein levels (OR, 1.01 for each mg/L increase; 95% CI, 1.00 to 1.01) as leading risk factors.
The analysis also found that patients who received antibiotics were more likely to have drug-related complications than those who didn't (4.9% vs 2.7%; OR, 1.84; 95% CI, 1.45 to 2.32).
The authors note that the percentage of COVID-19 patients who received antibiotics is similar to what's been found in other studies, and that the high prescribing rate contrasts with the low incidence of bacterial coinfection or superinfection in the cohort; only 10% of patients had confirmed pulmonary superinfection, and 2% had superinfection of another origin.
"Widespread antibiotic prescribing carries an increased risk of adverse reaction and probably other unwanted effects (such as possible increased bacterial resistances), without benefit," they wrote. "It is therefore essential to integrate antibiotic use optimization programs in patients with SARS-CoV2 infection. More research is needed to identify patients which warrant antibiotic prescription."
May 11 PLOS One study
Sierra Leone launches preventive Ebola vaccine drive near Guinea border
An Ebola vaccination campaign using the Johnson & Johnson vaccine launched yesterday in Sierra Leone near the Guinea border, a preventive step targeting 16,000 people in high-risk groups, the World Health Organization (WHO) African regional office said in a statement.
Immunization began in Kambia district, an important border crossing between Guinea and Sierra Leone. In the coming days, the effort will extend to eight other border districts. Guinea has had a recent outbreak that has not yet been declared over.
No Ebola cases in Sierra Leone have been detected since West Africa's massive outbreak that occurred from 2014 to 2016, but health officials want to ensure that frontline workers are protected. Included groups include those who would most likely have contact with an infected Ebola case: health workers, traditional healers, and commercial motor bike taxi drivers.
Sierra Leone's health ministry is leading the effort, with help from the WHO and the US Centers for Disease Prevention and Control.
The WHO and Johnson & Johnson donated the vaccine, which was recommended by the WHO vaccine advisory group in 2019. Known as Ad26.ZEBOV/MVA-BN, the vaccine is a prime-boost product designed to offer long-lasting protection and is given in two doses 56 days apart.
May 11 WHO African regional office statement